Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

GTHX

G1 Therapeutics Inc

Apr 29 • 04:00PM ET

3.72

Dollar change -0.27
Percentage change -6.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	18.81%	Shs Outstand	51.93M	Perf Week	-9.27%
Market Cap	194.18M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	-1.29%	Shs Float	42.38M	Perf Month	-13.89%
Income	-47.97M	PEG	-	EPS next Q	-0.20	Inst Own	24.07%	Short Float	5.71%	Perf Quarter	-18.06%
Sales	82.51M	P/S	2.35	EPS this Y	28.33%	Inst Trans	12.30%	Short Ratio	1.96	Perf Half Y	156.55%
Book/sh	0.68	P/B	5.46	EPS next Y	57.95%	ROA	-31.00%	Short Interest	2.42M	Perf Year	37.78%
Cash/sh	1.58	P/C	2.36	EPS next 5Y	-	ROE	-92.13%	52W Range	1.08 - 5.00	Perf YTD	21.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.38%	ROI	-52.55%	52W High	-25.60%	Beta	1.71
Dividend TTM	-	Quick Ratio	3.45	Sales past 5Y	18.67%	Gross Margin	91.28%	52W Low	244.44%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	3.87	EPS Y/Y TTM	72.68%	Oper. Margin	-47.91%	RSI (14)	40.47	Volatility	6.27% 7.39%
Employees	100	Debt/Eq	1.62	Sales Y/Y TTM	60.84%	Profit Margin	-58.13%	Recom	1.83	Target Price	8.50
Option/Short	Yes / Yes	LT Debt/Eq	1.58	EPS Q/Q	71.15%	Payout	-	Rel Volume	0.54	Prev Close	3.99
Sales Surprise	13.68%	EPS Surprise	24.43%	Sales Q/Q	45.10%	Earnings	May 01 BMO	Avg Volume	1.24M	Price	3.72
SMA20	-15.28%	SMA50	0.12%	SMA200	42.10%	Trades		Volume	691,138	Change	-6.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-23	Upgrade	JP Morgan	Underweight → Neutral	$7 → $10
Jan-03-23	Reiterated	Needham	Buy	$32 → $31
Nov-04-21	Downgrade	JP Morgan	Neutral → Underweight	$20 → $19
Oct-15-21	Resumed	BTIG Research	Buy	$51
Sep-30-21	Downgrade	JP Morgan	Overweight → Neutral	$24 → $20
Nov-17-20	Downgrade	Raymond James	Strong Buy → Outperform
Jun-26-20	Initiated	ROTH Capital	Buy	$55
Jan-21-20	Reiterated	H.C. Wainwright	Buy	$72 → $82
Aug-08-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-07-19	Initiated	B. Riley FBR	Buy	$55
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-20-18	Initiated	Raymond James	Strong Buy
Nov-08-18	Reiterated	Needham	Buy	$76 → $74
Sep-10-18	Resumed	BTIG Research	Buy	$80
May-29-18	Initiated	H.C. Wainwright	Buy	$61
May-18-18	Reiterated	Needham	Buy	$42 → $60

Show Previous Ratings

Apr-17-24 09:00AM	G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 (GlobeNewswire)
Apr-11-24 09:15AM	Biotech Innovations Paving the Way in Breast Cancer Fight (PR Newswire)
Apr-04-24 10:30AM	G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 04:20PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.32%
Mar-01-24 04:20PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.35%
10:21AM	Loading…
Feb-29-24 10:21AM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 11:09PM	Q4 2023 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +38.75%
07:40AM	G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:51AM	G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 (GuruFocus.com)
06:30AM	G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Feb-27-24 08:30AM	G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-15-24 08:30AM	G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024 (GlobeNewswire)
Feb-13-24 08:15AM	Why Is G1 Therapeutics (GTHX) Stock Down 45% Today? (InvestorPlace) -53.12%
Feb-12-24 04:05PM	G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee (GlobeNewswire)
Jan-08-24 06:45AM	G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +17.87%
05:02PM	Loading…
Jan-03-24 05:02PM	Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc (GuruFocus.com)
09:00AM	G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 04:51PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-23 11:05PM	Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics Inc (GuruFocus.com) -35.39%
Dec-05-23 09:26AM	G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy (GlobeNewswire) -8.00%
Dec-01-23 04:27PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.38%
Nov-29-23 08:37PM	G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-02-23 09:46AM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript (Insider Monkey) +21.64%
Nov-01-23 11:49PM	Q3 2023 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -18.79%
09:45AM	G1 Therapeutics Inc (GTHX) Reports Q3 2023 Earnings: $12.3 Million in Total Revenue (GuruFocus.com)
06:30AM	G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Oct-27-23 07:00AM	Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (GlobeNewswire)
Oct-26-23 10:02AM	Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +6.62%
Oct-25-23 10:01AM	Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-18-23 08:00AM	G1 Therapeutics' COSELA (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO) (GlobeNewswire)
07:30AM	Loading…
07:30AM	G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023 (GlobeNewswire)
Oct-16-23 09:00AM	G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium (GlobeNewswire) +5.26%
Sep-18-23 07:00AM	Black Diamond Therapeutics Announces CEO Transition (GlobeNewswire)
Sep-05-23 11:00AM	G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 04:15PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 07:45AM	G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Jul-31-23 02:30PM	G1 Therapeutics to Participate in Two August Investor Conferences (GlobeNewswire)
08:30AM	New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (GlobeNewswire)
Jul-27-23 09:42AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are individual investors with 46% stake, while 38% is held by institutions (Simply Wall St.)
Jul-26-23 09:00AM	G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023 (GlobeNewswire)
Jul-06-23 04:15PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-23 09:17AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Path To Profitability (Simply Wall St.)
07:13AM	Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy (GlobeNewswire)
Jun-01-23 04:40PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-22-23 04:45PM	G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel (GlobeNewswire)
May-16-23 07:30AM	New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer (GlobeNewswire) -7.19%
May-10-23 07:31AM	New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC) (GlobeNewswire)
May-08-23 06:02AM	Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX) (Simply Wall St.) -5.19%
May-05-23 06:12AM	G1 Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-03-23 02:20PM	RTP drug developer adds $30M to extend cash runway (American City Business Journals)
07:45AM	G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
May-01-23 05:00PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.32%
Apr-26-23 12:45PM	G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 (GlobeNewswire)
Apr-18-23 10:16AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shares Lagging The Industry But So Is The Business (Simply Wall St.)
Apr-12-23 12:00PM	G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Apr-11-23 12:30PM	G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 09:55PM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2022 Earnings Call Transcript (Insider Monkey)
12:01AM	Q4 2022 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-01-23 07:55AM	G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (GlobeNewswire)
Feb-28-23 02:10PM	G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-22-23 10:00AM	G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023 (GlobeNewswire)
Feb-17-23 07:40AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) latest 46% decline adds to one-year losses, institutional investors may consider drastic measures (Simply Wall St.)
Feb-16-23 10:01AM	Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-15-23 10:00AM	G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) +6.07%
Feb-13-23 01:33PM	G1 Therapeutics stock plummets 50% after trial cut short for cancer drug (American City Business Journals) -53.16%
08:03AM	G1 to discontinue study of colorectal cancer treatment (MarketWatch)
07:00AM	G1 Therapeutics Shelves Pivotal Colorectal Trial, After Trilaciclib Triplet Therapy Favored Placebo Arm (Benzinga)
06:00AM	G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) (GlobeNewswire)
Feb-09-23 08:00AM	First Prescription for COSELA® (trilaciclib) Issued in China (PR Newswire)
Feb-01-23 04:46PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-23 07:00AM	G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire)
Jan-09-23 06:30AM	G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib (GlobeNewswire)
Jan-04-23 11:01AM	G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial (Benzinga)
06:30AM	G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023 (GlobeNewswire)
Jan-03-23 02:00PM	G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference (GlobeNewswire) +5.52%
Dec-07-22 06:04PM	Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment (GlobeNewswire)
Dec-01-22 11:41PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-22 10:09PM	G1 Therapeutics raises $50M to help lift sales for cancer drug (American City Business Journals)
Nov-23-22 10:30AM	G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-22-22 04:01PM	G1 Therapeutics Announces Closing of Offering of Common Stock (GlobeNewswire)
Nov-17-22 08:12PM	G1 Therapeutics Announces Pricing of Offering of Common Stock (GlobeNewswire)
04:01PM	G1 Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-03-22 08:17AM	Newsflash: G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-02-22 10:19AM	G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug (Benzinga) -24.75%
07:45AM	G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights (GlobeNewswire)
06:28AM	Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC) (GlobeNewswire)
Nov-01-22 05:40PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-22 09:40AM	Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-26-22 09:26AM	G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer (GlobeNewswire)
Oct-21-22 06:42AM	G1 Therapeutics (NASDAQ:GTHX investor three-year losses grow to 52% as the stock sheds US$50m this past week (Simply Wall St.)
Oct-19-22 12:30PM	G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022 (GlobeNewswire) -8.88%
Oct-12-22 09:40AM	Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-10-22 06:30AM	G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC) (GlobeNewswire)
Oct-03-22 05:00PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-10-22 08:03AM	Institutional investors control 51% of G1 Therapeutics, Inc. (NASDAQ:GTHX) and were rewarded last week after stock increased 11% (Simply Wall St.)
Sep-07-22 08:00AM	G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +10.88%

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Umstead John W. V	Chief Financial Officer	Mar 18 '24	Sale	3.02	6,547	19,752	123,896	Mar 20 04:32 PM
Malik Rajesh	Chief Medical Officer	Feb 12 '24	Option Exercise	0.30	28,600	8,580	198,538	Feb 13 06:14 PM
Malik Rajesh	Chief Medical Officer	Feb 12 '24	Sale	4.62	28,600	132,143	169,938	Feb 13 06:14 PM
MURDOCK TERRY L	Chief Operating Officer	Jan 04 '24	Sale	2.94	721	2,121	103,638	Jan 08 06:00 AM
Avagliano Mark	Chief Business Officer	Jan 04 '24	Sale	2.94	721	2,121	117,834	Jan 08 06:02 AM
Malik Rajesh	Chief Medical Officer	Jan 04 '24	Sale	2.94	721	2,121	169,938	Jan 08 06:03 AM
Umstead John W. V	Chief Financial Officer	Jan 04 '24	Sale	2.94	111	327	130,443	Jan 08 06:04 AM
Bailey John E. (Jack) Jr.	President and CEO	Jan 03 '24	Sale	3.12	11,686	36,447	489,594	Jan 08 06:02 AM
Avagliano Mark	Chief Business Officer	Jan 03 '24	Sale	3.12	3,360	10,480	118,555	Jan 08 06:02 AM
MURDOCK TERRY L	Chief Operating Officer	Jan 03 '24	Sale	3.12	3,019	9,416	104,359	Jan 08 06:00 AM
Malik Rajesh	Chief Medical Officer	Jan 03 '24	Sale	3.12	3,019	9,416	170,659	Jan 08 06:03 AM
Perry Andrew	Chief Commercial Officer	Jan 03 '24	Sale	3.12	2,413	7,526	87,102	Jan 08 06:03 AM
Umstead John W. V	Chief Financial Officer	Jan 03 '24	Sale	3.12	632	1,971	130,554	Jan 08 06:04 AM
Bailey John E. (Jack) Jr.	President and CEO	Jan 02 '24	Sale	3.27	32,983	108,006	400,580	Jan 02 07:44 PM
Malik Rajesh	Chief Medical Officer	Dec 11 '23	Option Exercise	0.36	33,839	12,081	157,817	Dec 13 04:45 PM
Malik Rajesh	Chief Medical Officer	Dec 11 '23	Sale	3.41	33,839	115,522	136,378	Dec 13 04:45 PM
Velleca Mark A.	Director	Aug 08 '23	Option Exercise	0.39	60,000	23,156	173,286	Aug 10 04:11 PM
Velleca Mark A.	Director	Aug 08 '23	Sale	2.00	60,000	119,974	116,000	Aug 10 04:11 PM
Bailey John E. (Jack) Jr.	President and CEO	Jul 05 '23	Sale	2.45	2,719	6,672	433,563	Jul 07 04:07 PM
MURDOCK TERRY L	Chief Operating Officer	Jul 05 '23	Sale	2.45	1,361	3,339	70,078	Jul 07 04:08 PM
Malik Rajesh	Chief Medical Officer	Jul 05 '23	Sale	2.45	1,361	3,339	136,378	Jul 07 04:08 PM
Perry Andrew	Chief Commercial Officer	Jul 05 '23	Sale	2.45	355	871	55,945	Jul 07 04:08 PM

Open in Screener

STIM

Neuronetics Inc

Apr 29 • 04:00PM ET

3.54

Dollar change +0.05
Percentage change 1.29	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFAS AVSC DFAC

Index	-	P/E	-	EPS (ttm)	-1.06	Insider Own	10.42%	Shs Outstand	29.09M	Perf Week	-5.48%
Market Cap	105.20M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-7.06%	Shs Float	26.66M	Perf Month	-25.74%
Income	-30.19M	PEG	-	EPS next Q	-0.31	Inst Own	61.81%	Short Float	0.22%	Perf Quarter	5.52%
Sales	71.35M	P/S	1.47	EPS this Y	11.87%	Inst Trans	-1.98%	Short Ratio	0.35	Perf Half Y	236.67%
Book/sh	1.18	P/B	3.01	EPS next Y	31.11%	ROA	-25.95%	Short Interest	0.06M	Perf Year	56.42%
Cash/sh	2.04	P/C	1.74	EPS next 5Y	-	ROE	-66.17%	52W Range	1.03 - 5.07	Perf YTD	21.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	17.12%	ROI	-31.51%	52W High	-30.27%	Beta	2.49
Dividend TTM	-	Quick Ratio	4.33	Sales past 5Y	7.39%	Gross Margin	69.66%	52W Low	243.20%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	4.73	EPS Y/Y TTM	23.59%	Oper. Margin	-42.82%	RSI (14)	36.28	Volatility	6.64% 7.15%
Employees	203	Debt/Eq	1.83	Sales Y/Y TTM	9.42%	Profit Margin	-42.31%	Recom	1.50	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	1.80	EPS Q/Q	39.25%	Payout	-	Rel Volume	0.21	Prev Close	3.49
Sales Surprise	2.33%	EPS Surprise	26.75%	Sales Q/Q	11.63%	Earnings	May 07 BMO	Avg Volume	166.46K	Price	3.54
SMA20	-13.19%	SMA50	-9.20%	SMA200	44.15%	Trades		Volume	34,809	Change	1.29%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-13-21	Downgrade	BTIG Research	Buy → Neutral
Jan-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Feb-06-20	Initiated	BTIG Research	Buy	$11
Jul-24-18	Initiated	Canaccord Genuity	Buy

Apr-23-24 04:30PM	Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call (GlobeNewswire)
Apr-10-24 08:31AM	New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital (GlobeNewswire)
Apr-01-24 10:52AM	Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression (Zacks)
Mar-27-24 04:30PM	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:10AM	Neuronetics wins FDA clearance for device to treat adolescents with depression (MedTech Dive)
08:30AM	Loading…
Mar-25-24 08:30AM	NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression (GlobeNewswire) +11.35%
Mar-08-24 08:06AM	Neuronetics (STIM) Progresses in MRD and TRD With New Deal (Zacks)
Mar-07-24 02:00PM	Neuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023 (GuruFocus.com)
10:16AM	Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:22AM	Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network (GlobeNewswire)
Mar-05-24 11:39PM	Q4 2023 Neuronetics Inc Earnings Call (Thomson Reuters StreetEvents) +15.41%
08:40AM	Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:46AM	Neuronetics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results (GlobeNewswire)
Feb-20-24 08:30AM	Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call (GlobeNewswire)
08:32AM	Loading…
Feb-12-24 08:32AM	Neuronetics Launches Latest Evolution in its TrakStar Patient Data Management System (GlobeNewswire)
Feb-06-24 08:28AM	NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update (GlobeNewswire) +6.67%
Jan-08-24 08:30AM	Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire) -6.35%
Dec-18-23 08:49AM	Neuronetics Receives 510(k) Clearance for NeuroSite Coil Placement Accessory (GlobeNewswire)
Dec-04-23 08:56AM	NeuroStar TMS Receives Expanded Regulatory Approval in Japan (GlobeNewswire) +8.87%
Nov-15-23 04:15PM	Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 08:57AM	NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements (GlobeNewswire)
Nov-09-23 08:32AM	Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage (GlobeNewswire) -11.30%
Nov-08-23 01:16PM	Neuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:57AM	Neuronetics Inc (STIM) Reports 8% Revenue Growth in Q3 2023 (GuruFocus.com) +8.11%
07:43AM	Neuronetics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Neuronetics Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Nov-06-23 04:30PM	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.50%
Oct-24-23 08:30AM	Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call (GlobeNewswire)
Oct-16-23 08:56AM	Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes (GlobeNewswire)
09:21AM	Loading…
Oct-03-23 09:21AM	Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility (GlobeNewswire) -6.87%
Sep-12-23 08:56AM	In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression (GlobeNewswire)
Aug-21-23 08:56AM	NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards (GlobeNewswire)
Aug-18-23 09:02PM	Cannell Capital LLC Reduces Stake in Neuronetics Inc (GuruFocus.com)
Aug-14-23 09:02AM	Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform (GlobeNewswire)
Aug-11-23 12:00PM	Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-08-23 08:22AM	Neuronetics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results (GlobeNewswire)
Aug-04-23 04:30PM	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-25-23 08:30AM	Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call (GlobeNewswire)
Jul-19-23 08:56AM	Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans (GlobeNewswire)
Jul-17-23 08:46AM	NeuroStar Achieves Milestone Regulatory Clearance in South Korea (GlobeNewswire)
Jul-11-23 08:56AM	NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player (GlobeNewswire)
Jun-12-23 11:25AM	Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers (Zacks)
11:18AM	LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure (Zacks)
08:59AM	Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy (GlobeNewswire)
Jun-09-23 09:50AM	Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger (Zacks)
08:53AM	Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture (Zacks)
Jun-08-23 12:18PM	Neuronetics, Inc. (NASDAQ:STIM) Could Be Riskier Than It Looks (Simply Wall St.)
09:31AM	Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan (Zacks)
Jun-06-23 11:19AM	Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes (Zacks)
08:04AM	Bruker's (BRKR) Latest Workflows to Aid Applied Markets (Zacks)
Jun-02-23 10:26AM	Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes (Zacks)
08:33AM	Neogen (NEOG) Introduces 2 Assays for Histamine Detection (Zacks)
Jun-01-23 08:39AM	LabCorp (LH) Expands Precision Oncology With Biopsy Test (Zacks)
May-31-23 09:16AM	Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23 (Zacks)
May-30-23 01:50PM	Neuronetics investing in NeuroStar awareness as drug-free treatment alternative for depression (News Direct) -5.14%
May-29-23 02:06AM	Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised) (Zacks)
May-26-23 08:59AM	Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan (GlobeNewswire) +6.18%
May-25-23 12:25PM	Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio (Zacks)
May-24-23 04:30PM	Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
09:34AM	Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Zacks)
May-23-23 10:10AM	Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs (Zacks)
08:46AM	New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction (GlobeNewswire)
May-22-23 08:01AM	Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays (Zacks)
May-18-23 10:16AM	Illumina (ILMN) Progresses in Pathogen Genomic Technologies (Zacks) -6.88%
May-17-23 11:09AM	Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo (Zacks)
May-15-23 08:56AM	Neuronetics Wins 2023 Bell Seal for Workplace Mental Health (GlobeNewswire)
07:58AM	Integra (IART) Builds Advanced R&D Facility in New Jersey (Zacks)
May-09-23 05:00PM	Neuronetics to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) +27.27%
08:55AM	Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Neuronetics Reports Record First Quarter 2023 Financial and Operating Results (GlobeNewswire)
May-08-23 08:47AM	Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR (GlobeNewswire)
May-05-23 08:30AM	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-23 08:58AM	Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting (GlobeNewswire)
May-02-23 09:01AM	NeuroStar® Expands Tap Into Possibility Campaign in Honor of Mental Health Awareness Month (GlobeNewswire)
May-01-23 08:46AM	Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer (GlobeNewswire)
Apr-28-23 04:11PM	Neuronetics Announces Expanded TMS Access through United HealthCare (GlobeNewswire)
Apr-25-23 08:30AM	Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call (GlobeNewswire)
Apr-18-23 02:14PM	Further weakness as Neuronetics (NASDAQ:STIM) drops 11% this week, taking one-year losses to 25% (Simply Wall St.)
Apr-13-23 08:58AM	Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy (GlobeNewswire)
Apr-06-23 04:16PM	NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities (GlobeNewswire) -9.38%
Apr-04-23 08:30AM	Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note (GlobeNewswire)
Mar-16-23 08:56AM	NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA (GlobeNewswire)
Mar-08-23 10:02PM	Neuronetics, Inc. (NASDAQ:STIM) Q4 2022 Earnings Call Transcript (Insider Monkey) -10.93%
12:44AM	Q4 2022 Neuronetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 08:45AM	Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -19.19%
07:30AM	Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results (GlobeNewswire)
Mar-02-23 04:02PM	Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives (GlobeNewswire) -5.26%
Feb-27-23 04:30PM	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-23-23 08:56AM	Neuronetics Expands NeuroStar® Advanced Therapys Proprietary TrakStar® Platform (GlobeNewswire) -10.02%
Feb-22-23 04:35PM	Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call (GlobeNewswire)
Feb-21-23 08:53AM	Neuronetics Sponsors the 5th International Brain Stimulation Conference (GlobeNewswire)
Feb-16-23 04:12PM	Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer (GlobeNewswire)
Feb-10-23 04:15PM	Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners (GlobeNewswire)
Jan-19-23 10:50AM	Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS (Benzinga)
08:30AM	Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership (GlobeNewswire)
Jan-18-23 04:29PM	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.35%
Jan-17-23 08:32AM	Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health (GlobeNewswire)
Jan-10-23 12:27PM	Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay (Benzinga)

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Feb 29 '24	Sale	2.94	6,026	17,716	389,333	Mar 01 05:02 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Feb 28 '24	Sale	3.16	22,377	70,711	395,359	Mar 01 05:02 PM
Furlong Stephen	EVP, CFO and Treasurer	Feb 28 '24	Sale	3.16	3,985	12,593	483,776	Feb 29 05:02 PM
Furlong Stephen	EVP, CFO and Treasurer	Feb 27 '24	Sale	3.33	21,272	70,836	487,761	Feb 29 05:02 PM
Sullivan Keith J	President and CEO	Feb 26 '24	Sale	3.30	20,292	66,964	1,372,278	Feb 28 05:02 PM
Sullivan Keith J	President and CEO	Feb 23 '24	Sale	3.23	20,750	67,022	1,392,570	Feb 26 05:21 PM
Sullivan Keith J	President and CEO	Feb 22 '24	Sale	3.23	20,851	67,349	1,413,320	Feb 26 05:21 PM
Sullivan Keith J	President and CEO	Feb 20 '24	Sale	2.96	23,958	70,916	1,434,171	Feb 22 05:02 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Feb 14 '24	Sale	3.38	15,621	52,799	417,736	Feb 16 05:11 PM
Furlong Stephen	EVP, CFO and Treasurer	Feb 09 '24	Sale	3.51	14,710	51,632	509,033	Feb 13 06:00 PM
Furlong Stephen	EVP, CFO and Treasurer	Feb 06 '24	Sale	3.39	5,813	19,706	523,743	Feb 07 05:41 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Feb 06 '24	Sale	3.39	5,385	18,255	433,357	Feb 07 05:42 PM
Sullivan Keith J	President and CEO	Jan 11 '24	Sale	3.16	9,516	30,071	1,158,129	Jan 12 06:00 PM
Sullivan Keith J	President and CEO	Jan 10 '24	Sale	3.01	10,013	30,139	1,167,645	Jan 12 06:00 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Dec 21 '23	Sale	2.52	11,663	29,391	348,742	Dec 21 07:42 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Dec 20 '23	Sale	2.70	11,664	31,493	360,405	Dec 21 07:42 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Dec 19 '23	Sale	2.24	11,664	26,127	372,069	Dec 21 07:42 PM
Furlong Stephen	EVP, CFO and Treasurer	Oct 06 '23	Sale	1.16	1,499	1,731	429,556	Oct 10 05:10 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Oct 06 '23	Sale	1.16	1,469	1,697	383,733	Oct 10 05:12 PM
Sullivan Keith J	President and CEO	Jul 21 '23	Sale	2.04	6,551	13,364	1,177,658	Jul 25 07:50 PM
Sullivan Keith J	President and CEO	Jul 20 '23	Sale	2.06	6,510	13,411	1,184,209	Jul 21 06:15 PM
Sullivan Keith J	President and CEO	Jul 19 '23	Sale	2.07	6,479	13,412	1,190,719	Jul 21 06:15 PM
MACAN WILLIAM ANDREW	EVP, GC, CCO and CS	Jul 11 '23	Sale	2.13	2,645	5,634	385,202	Jul 12 08:35 PM
BAKEWELL JOHN K	Director	May 24 '23	Sale	2.70	14,400	38,880	77,988	May 26 04:10 PM

Open in Screener

RGEN

Repligen Corp.

Apr 29 • 04:00PM ET

166.14

Dollar change -0.44
Percentage change -0.26	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB VXF VBK IBB IJK FBT VHT IWR

Index	-	P/E	230.53	EPS (ttm)	0.72	Insider Own	7.02%	Shs Outstand	55.77M	Perf Week	5.50%
Market Cap	9.27B	Forward P/E	80.88	EPS next Y	2.05	Insider Trans	-0.74%	Shs Float	51.85M	Perf Month	-9.67%
Income	41.58M	PEG	12.84	EPS next Q	0.30	Inst Own	105.03%	Short Float	8.85%	Perf Quarter	-13.56%
Sales	638.76M	P/S	14.51	EPS this Y	-16.68%	Inst Trans	1.47%	Short Ratio	9.56	Perf Half Y	35.62%
Book/sh	35.35	P/B	4.70	EPS next Y	40.87%	ROA	1.55%	Short Interest	4.59M	Perf Year	14.46%
Cash/sh	13.47	P/C	12.33	EPS next 5Y	17.96%	ROE	2.14%	52W Range	110.45 - 211.13	Perf YTD	-7.60%
Dividend Est.	-	P/FCF	123.66	EPS past 5Y	15.08%	ROI	1.59%	52W High	-21.31%	Beta	1.02
Dividend TTM	-	Quick Ratio	5.75	Sales past 5Y	31.42%	Gross Margin	44.49%	52W Low	50.42%	ATR (14)	6.29
Dividend Ex-Date	-	Current Ratio	7.02	EPS Y/Y TTM	-77.69%	Oper. Margin	9.71%	RSI (14)	41.64	Volatility	3.70% 3.29%
Employees	1783	Debt/Eq	0.36	Sales Y/Y TTM	-20.31%	Profit Margin	6.51%	Recom	1.50	Target Price	212.30
Option/Short	Yes / Yes	LT Debt/Eq	0.32	EPS Q/Q	-153.51%	Payout	0.00%	Rel Volume	0.87	Prev Close	166.58
Sales Surprise	-8.57%	EPS Surprise	1.29%	Sales Q/Q	-16.61%	Earnings	May 01 BMO	Avg Volume	479.69K	Price	166.14
SMA20	-2.25%	SMA50	-10.03%	SMA200	-2.60%	Trades		Volume	426,055	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-23	Downgrade	The Benchmark Company	Buy → Hold
Jul-20-23	Initiated	Wells Fargo	Overweight	$185
Jul-05-23	Resumed	JP Morgan	Overweight	$220
Mar-28-23	Initiated	The Benchmark Company	Buy	$230
Dec-14-22	Initiated	Deutsche Bank	Hold	$180
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$190
Jul-20-22	Initiated	UBS	Buy	$213
Oct-14-21	Initiated	Exane BNP Paribas	Outperform	$330
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$241
Aug-24-20	Reiterated	H.C. Wainwright	Buy	$151 → $168
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$143 → $151
May-07-20	Reiterated	H.C. Wainwright	Buy	$100 → $143
Mar-23-20	Reiterated	H.C. Wainwright	Buy	$110 → $100
Nov-15-19	Initiated	Stifel	Buy
Nov-01-19	Upgrade	First Analysis Sec	Outperform → Strong Buy	$107 → $110
Oct-15-19	Initiated	SVB Leerink	Outperform	$100
Aug-28-19	Reiterated	First Analysis Sec	Outperform	$95 → $107
Aug-23-19	Resumed	Stephens	Overweight
Jul-22-19	Upgrade	H.C. Wainwright	Neutral → Buy	$110
Dec-17-18	Upgrade	CL King	Neutral → Buy

Show Previous Ratings

Apr-23-24 11:43AM	Should be Confident in Repligen Corporation (RGEN)'s Long-Term Growth Potential? (Insider Monkey) +8.76%
Apr-17-24 07:30AM	Repligen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-12-24 10:07AM	Artisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share Appreciation (Insider Monkey)
09:49AM	Should You Sell Pool Corporation (POOL)? (Insider Monkey)
Mar-19-24 07:30AM	Repligen Appoints Maggie A. Pax to Board of Directors (GlobeNewswire)
01:18AM	Loading…
Mar-12-24 01:18AM	Repligen Corp CEO Anthony Hunt Sells 16,707 Shares (GuruFocus.com)
Feb-27-24 02:02AM	Repligen Corp COO James Bylund Sells 4,373 Shares (GuruFocus.com)
Feb-24-24 12:03AM	Decoding Repligen Corp (RGEN): A Strategic SWOT Insight (GuruFocus.com)
Feb-22-24 11:24AM	Repligen Corporation (NASDAQ:RGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:39AM	Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y (Zacks)
Feb-21-24 08:45AM	Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates (Zacks)
08:12AM	Repligen Corp (RGEN) Reports Decline in 2023 Revenue and Net Income (GuruFocus.com)
07:51AM	Repligen: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-07-24 07:30AM	Repligen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
12:10PM	Loading…
Jan-31-24 12:10PM	Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-29-24 05:09AM	Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength? (Zacks)
Dec-19-23 07:30AM	Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 04:49AM	Here's Why Repligen Corporation (RGEN) Rose 13% in Q3 (Insider Monkey)
Dec-07-23 07:30AM	Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements (GlobeNewswire)
Nov-30-23 11:31AM	Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-15-23 07:15AM	Does Repligen Corp. (RGEN) Have a Bright Future? (Insider Monkey)
Nov-14-23 02:01PM	UPDATE Repligen Announces Publication of the Company's 2022 Sustainability Report (GlobeNewswire) +5.55%
07:30AM	Repligen Announces Publication of the Company's 2022 Sustainability Report (GlobeNewswire)
Nov-07-23 07:30AM	Repligen Corporation to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 07:30AM	Repligen Launches TangenX SC as First-to-Market Holder-Free Self-Contained TFF Device (GlobeNewswire)
Nov-01-23 12:10PM	Repligen Corporation (NASDAQ:RGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
11:46AM	Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat (Zacks)
12:04AM	Q3 2023 Repligen Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-31-23 09:41AM	Repligen Corp (RGEN) Reports Q3 2023 Earnings: Revenue Down 30% Y/Y (GuruFocus.com) +17.86%
09:12AM	Loading…
09:12AM	Repligen Q3 Results Top Estimates; Boosts FY23 Earnings Outlook (RTT News)
08:50AM	Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:41AM	Repligen: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance (GlobeNewswire)
Oct-25-23 10:01AM	Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for (Zacks) -10.99%
Oct-24-23 10:00AM	Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline (Zacks)
Oct-17-23 11:44AM	Repligen (RGEN)'s Hidden Value: An In-Depth Analysis of Its Market Worth (GuruFocus.com)
07:30AM	Repligen to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-02-23 07:30AM	Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer (GlobeNewswire)
Sep-27-23 06:51AM	Repligen (RGEN) to Acquire Fluid Management Company Metenova (Zacks)
Sep-26-23 12:41PM	Waltham's Repligen to acquire Swedish firm (American City Business Journals)
07:30AM	Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova (GlobeNewswire)
Sep-14-23 10:10AM	Moderna (MRNA) Surges 3.2%: Is This an Indication of Further Gains? (Zacks)
Sep-12-23 07:30AM	Repligen Appoints Jason K. Garland as Chief Financial Officer (GlobeNewswire)
Sep-06-23 03:06AM	Reasons For the Decline of Repligen Corporation (RGEN) (Insider Monkey)
Sep-01-23 12:19PM	Drug Developer Stocks Are Risky. Why a Picks-and-Shovels Approach Makes Sense. (Barrons.com)
11:31AM	Why Is Repligen (RGEN) Up 2.9% Since Last Earnings Report? (Zacks)
07:30AM	Repligen Corporation to Present at Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-21-23 06:53AM	What Makes Repligen Corporation (RGEN) a Quality Investment? (Insider Monkey)
Aug-17-23 08:00AM	Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification (GlobeNewswire)
Aug-10-23 09:39AM	Multiple Headwinds Impacted Repligen Corp. (RGEN)s Performance in Q2 (Insider Monkey)
Aug-09-23 06:10AM	News Flash: 14 Analysts Think Repligen Corporation (NASDAQ:RGEN) Earnings Are Under Threat (Simply Wall St.)
Aug-03-23 11:19AM	Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance (Zacks)
Aug-02-23 08:55AM	Repligen (RGEN) Q2 Earnings Surpass Estimates (Zacks)
07:49AM	Repligen: Q2 Earnings Snapshot (AP Finance)
07:30AM	Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance (GlobeNewswire)
Jul-31-23 09:08AM	What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate? (Simply Wall St.)
Jul-26-23 10:02AM	Earnings Preview: Repligen (RGEN) Q2 Earnings Expected to Decline (Zacks)
Jul-25-23 11:40AM	EXEL or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
Jul-20-23 10:01AM	Estee Lauder downgraded, AB InBev upgraded: Wall Street's top analyst calls (The Fly)
Jul-19-23 07:30AM	Repligen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-10-23 08:34AM	Are Options Traders Betting on a Big Move in Repligen (RGEN) Stock? (Zacks)
Jun-30-23 10:54AM	Repligen's (NASDAQ:RGEN) five-year total shareholder returns outpace the underlying earnings growth (Simply Wall St.)
Jun-21-23 08:00PM	RGEN: Lowering target price to $157.00 (Argus Research)
Jun-07-23 11:30AM	Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report? (Zacks)
Jun-02-23 11:31AM	Qiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 11:31AM	Why Is Repligen (RGEN) Up 2.7% Since Last Earnings Report? (Zacks)
May-31-23 07:30AM	Repligen Corporation to Present at Upcoming Investor Conferences (GlobeNewswire)
May-30-23 12:09PM	If EPS Growth Is Important To You, Repligen (NASDAQ:RGEN) Presents An Opportunity (Simply Wall St.)
May-09-23 05:52PM	Repligen Corporation (NASDAQ:RGEN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-03-23 01:20PM	Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance (Zacks)
May-02-23 11:36PM	Q1 2023 Repligen Corp Earnings Call (Thomson Reuters StreetEvents)
08:55AM	Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:52AM	Repligen: Q1 Earnings Snapshot (AP Finance)
07:30AM	Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance (GlobeNewswire)
07:02AM	Is Repligen Corporation (RGEN) a Best-In-Class Stock in Terms of Growth and Profitability? (Insider Monkey)
May-01-23 07:43AM	Should Weakness in Repligen Corporation's (NASDAQ:RGEN) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? (Simply Wall St.)
Apr-26-23 08:00PM	RGEN: Lowering target price to $156.00 (Argus Research)
10:02AM	Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-25-23 02:07PM	Why Repligen Stock Is Sinking Today (Motley Fool) -11.09%
10:01AM	Repligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-18-23 07:30AM	Repligen to Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-11-23 02:41PM	A Look At The Fair Value Of Repligen Corporation (NASDAQ:RGEN) (Simply Wall St.)
Mar-24-23 11:30AM	Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report? (Zacks)
Mar-14-23 07:30AM	Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum (GlobeNewswire)
Feb-23-23 06:28PM	Repligen Corporation (NASDAQ:RGEN) Q4 2022 Earnings Call Transcript (Insider Monkey) +8.02%
01:41PM	Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates (Zacks)
05:54AM	Repligen Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Feb-22-23 08:55AM	Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:30AM	Repligen Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-20-23 06:34AM	Why Repligen Corporation (NASDAQ:RGEN) Could Be Worth Watching (Simply Wall St.)
Feb-09-23 07:30AM	Repligen Appoints Martin D. Madaus to Board of Directors (GlobeNewswire)
Feb-08-23 07:30AM	Repligen to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Jan-21-23 09:51AM	Repligen (NASDAQ:RGEN) stock performs better than its underlying earnings growth over last five years (Simply Wall St.)
Jan-19-23 03:10AM	Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock? (Zacks)
Jan-13-23 08:30AM	Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? (Zacks)
Jan-12-23 05:00PM	Why Shares of Repligen Rose This Week (Motley Fool)
11:40AM	HZNP vs. RGEN: Which Stock Is the Better Value Option? (Zacks)
Jan-03-23 07:30AM	Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 10:56AM	If EPS Growth Is Important To You, Repligen (NASDAQ:RGEN) Presents An Opportunity (Simply Wall St.)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KURIYEL RALF	Senior VP, R&D	Mar 11 '24	Option Exercise	86.10	1,271	109,433	27,777	Mar 12 08:24 PM
KURIYEL RALF	Senior VP, R&D	Mar 11 '24	Sale	193.73	3,517	681,348	24,260	Mar 12 08:24 PM
Hunt Anthony	Chief Executive Officer	Mar 08 '24	Option Exercise	16.55	1	17	201,956	Mar 11 07:43 PM
Hunt Anthony	Chief Executive Officer	Mar 08 '24	Sale	197.44	16,707	3,298,632	185,249	Mar 11 07:43 PM
DAWES KAREN A	Director	Feb 27 '24	Option Exercise	42.07	4,626	194,616	88,367	Feb 28 09:56 PM
DAWES KAREN A	Director	Feb 27 '24	Sale	193.35	1,000	193,350	87,367	Feb 28 09:56 PM
Bylund James	Chief Operating Officer	Feb 23 '24	Option Exercise	94.33	940	88,670	18,508	Feb 26 08:38 PM
Bylund James	Chief Operating Officer	Feb 23 '24	Sale	198.08	4,373	866,204	14,135	Feb 26 08:38 PM
Gebski Christine	See Remarks	Nov 10 '23	Sale	147.13	3,788	557,328	28,787	Nov 13 05:10 PM
DAWES KAREN A	Director	Aug 29 '23	Option Exercise	18.12	7,392	133,943	84,591	Aug 30 04:06 PM
DAWES KAREN A	Director	Aug 29 '23	Sale	171.38	850	145,673	83,741	Aug 30 04:06 PM
Madaus Martin D	Director	May 08 '23	Buy	156.18	500	78,090	1,611	May 08 09:15 PM
Madaus Martin D	Director	May 05 '23	Buy	159.19	500	79,595	1,111	May 08 09:15 PM
Madaus Martin D	Director	May 04 '23	Buy	161.15	500	80,575	611	May 08 09:15 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

GTHX

G1 Therapeutics Inc

STIM

Neuronetics Inc

RGEN

Repligen Corp.

Upgrade your FINVIZ experience